US 9,809,803 B2
Mitogen-activated protein kinase-dependent recombinant vaccinia virus (MD-RVV) and use thereof
Takafumi Nakamura, Yonago (JP)
Assigned to National University Corporation Tottori University, Tottori (JP); and The Chemo-Sero-Therapeutic Research Institute, Kumamoto (JP)
Appl. No. 15/38,145
Filed by National University Corporation Tottori University, Tottori-shi, Tottori (JP); and The Chemo-Sero-Therapeutic Research Institute, Kumamoto-shi, Kumamoto (JP)
PCT Filed Nov. 20, 2014, PCT No. PCT/JP2014/081484
§ 371(c)(1), (2) Date May 20, 2016,
PCT Pub. No. WO2015/076422, PCT Pub. Date May 28, 2015.
Claims priority of application No. 2013-241299 (JP), filed on Nov. 21, 2013.
Prior Publication US 2016/0281066 A1, Sep. 29, 2016
Int. Cl. C07D 417/00 (2006.01); C12N 7/00 (2006.01); A61K 48/00 (2006.01); C12N 15/09 (2006.01); A61K 35/768 (2015.01)
CPC C12N 7/00 (2013.01) [A61K 35/768 (2013.01); A61K 48/00 (2013.01); C12N 15/09 (2013.01); C12N 2710/24121 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24162 (2013.01); C12N 2710/24171 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A mitogen-activated protein kinase-dependent vaccinia virus, which is deprived of functions of the vaccinia virus growth factor (VGF) and O1L, which does not grow in a normal cell but grows specifically in a cancer cell, and which has oncolytic properties of specifically damaging cancer cells.